| Biostar Pharm-B | 02563 | 23-May-25 | 25-Aug-25 | | The Company will change its accounting standards from HKFRS Accounting Standards to China Accounting Standards for Business Enterprises (CASBE) starting from the financial year of 2025. Daxin has confirmed that, except for the unresolved matter in relation to the qualified opinion about the existence, rights and obligations, completeness, accuracy and valuation of the underlying assets, including the Fund Investments, and liabilities of the Fund there are no other matters in connection with its retirement that need to be brought to the attention of the shareholders. |